Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Cladribine + HAG in Relapsed/Refractory AML
ChiCTR2300069327Phase 4Not yet recruiting
- Sponsor
- Southwest Hospital of Army Medical University
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of venetoclax in acute myeloid leukemia (AML), sponsored by Southwest Hospital of Army Medical University. Primary endpoint: Complete response rate (CR + CRi). Planned start Oct 2022; status: not yet recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2300069327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069327.